Aldeyra Therapeutics enrols first patient in Phase III GUARD study

Proliferative vitreoretinopathy is a rare retinal disease that causes severe retinal scarring and blindness. Credit: Kalea Jerielle on Unsplash.



  • Aldeyra Therapeutics enrols first patient in Phase III GUARD study